Why Longevity Products May Already Fall Under U.S. Drug Law

On November 7, 2026, Earth.com reported on a legal analysis published in Science by Camila Strassle and Holly Fernandez Lynch of the University of Pennsylvania and Patricia J. Zettler of Ohio State University. The analysis challenged the idea that marketing a product for longevity places it beyond existing U.S. drug rules.

Why intended use matters more than the anti-aging label

The authors’ central argument is that a disease-treatment claim is not the only basis for drug regulation. U.S. law also covers products intended to affect the body’s structure or function, which could include many products promoted for longevity. The relevance to healthspan is a distinction between what a product is intended to do and evidence that it adds years of good health. Legal classification addresses the former question; clinical research must address the latter.

Evidence type: A legal analysis, not an in vitro experiment, an animal-model study or a study in humans.

How to weigh the analysis and its limits

• The interpretation is not a product-by-product FDA ruling. “Anti-aging” is a marketing description rather than a classification that settles every case. According to Earth.com’s account, the authors argue that intended bodily effects can bring products within the drug definition even without treating aging as a disease. Their argument still requires attention to the particular product and its intended use.

The report cites hair-growth drugs and Botox for smoothing facial lines as examples of approvals for uses that do not target disease. Those examples support the authors’ reading of the law, rather than granting a shared status to everything marketed for longevity. The practical reading is to look for the specific intended effect and the specific regulatory claim. A clear way to compare evidence quality helps keep the legal argument separate from the strength of supporting research.

• The supplement rules qualify the broad argument. The Electronic Code of Federal Regulations allows qualifying structure/function statements for dietary supplements subject to requirements. A supplement bearing a disease claim can instead be regulated as a drug unless the claim is authorized. Earth.com also notes that dietary supplements generally do not need FDA approval before sale.

Those distinctions rule out the shortcut that all supplements making bodily-function claims are automatically unlawful drugs. They also make the product’s form relevant: the report says injected products and products applied to skin cannot qualify as dietary supplements. It says the same of patches and nasal sprays. A “research purposes only” label does not itself create an exemption from the law, according to the report.

For a reader assessing an advertisement, the useful question is which category the product is being offered under and whether its claims fit that category. Market availability alone does not answer that question.

• An existing approval does not establish a longevity use. Earth.com reports that no product has FDA approval specifically for anti-aging. It names metformin and rapamycin as substances with approvals for other purposes. Strassle told the outlet that products lacking anti-aging approval have not been proved safe or effective for that purpose.

The report distinguishes off-label prescribing of an already approved drug from use of a product with no approval. It describes off-label prescribing as having the strongest legal standing short of approval for aging. It also notes that drug makers generally cannot advertise off-label uses.

The useful comparison is therefore not simply “approved” versus “unapproved.” It is approval for which purpose, alongside evidence for the purpose being promoted. That is a question about the match between the claim and its support, not a conclusion that every unapproved longevity use has the same risk or outcome. Personal decisions about prescription use belong with qualified care.

• Healthspan endpoints remain unsettled. The report identifies a scientific bottleneck: researchers have not agreed on surrogate endpoints that reliably stand in for longer, healthier life. A surrogate endpoint is a substitute measure used in place of the outcome a study ultimately aims to establish. For longevity research, the challenge is connecting a near-term biological result to meaningful health over time.

Earth.com describes a May 2026 public meeting convened by the Reagan-Udall Foundation for the FDA and ARPA-H at which candidate measures were discussed. Discussion of candidates belongs to the work of developing standards. It does not supply a validated endpoint for a product claim.

When reading a study, ask what outcome was measured and whether the tested product matches the marketed purpose. Then ask what supports the link between that outcome and longer healthy life. The challenges of interpreting aging measurements are relevant here because a measurable change and a meaningful health outcome are different questions.

• A trial count does not show what those trials found. According to Earth.com, the National Institute on Aging established the Translational Geroscience Network to standardize research. The report says more than 80 trials are affiliated with it. That figure describes a research effort rather than a tally of successful longevity products.

The report also says many companies sell anti-aging products without studies establishing safety or effectiveness for that purpose. Those two facts describe different parts of the field: organized research and commercial availability. Neither should be used as a substitute for examining the evidence for an individual claim.

For evaluation, the next useful detail is the actual outcome reported by the relevant study. A network affiliation identifies a research connection; it does not state the result.

• An advisory recommendation is narrower than an approval. Earth.com reports that a July 2026 FDA advisory panel narrowly recommended adding several peptides to a list of substances pharmacies may compound. Some were used for longevity. The report also describes panelists’ financial interests and safety and effectiveness concerns raised by FDA staff.

Those details matter when assessing what the recommendation represents. The action concerned a compounding list, not a finding that the peptides extend healthy human life. Reading the type of decision is more informative than treating every favorable regulatory development as equivalent.

For readers following peptide claims, the practical distinction is between permission being discussed within a specific regulatory process and evidence for the advertised health outcome. The wording of a recommendation should stay attached to the question the panel considered.

• Animal examples supply legal context rather than human results. The report points to FDA signals about two drugs intended to extend dogs’ lives. It presents those developments as an analogy because the animal and human legal definitions are the same. The analogy concerns the reach of the definition, not evidence that a human longevity intervention works.

This is where the research model still matters in a legal story. An animal-focused regulatory example and a human clinical outcome answer different questions. The clearest reading keeps the legal analogy attached to its purpose rather than treating it as a bridge to human benefit.

When a longevity claim cites progress in animals, identify whether the supporting material concerns legal classification or measured health effects. Then judge the human claim against evidence from the population it concerns.

• Enforcement expectations are not settled outcomes. Earth.com says FDA enforcement discretion gives the agency latitude over whether to act. The possibility of lower enforcement priority under leadership friendly to the longevity industry is presented as the authors’ assessment. It is not an established prediction about what the agency will do.

Strassle also emphasizes oversight of whether products contain what labels state and in the amounts claimed. The authors argue that effective enforcement can protect companies investing in studies from competitors selling unproven products. That explains why the debate concerns product quality as well as evidence.

For readers, the practical point is to distinguish a regulatory framework from a forecast about how actively it will be enforced.

Why endpoint validation is the next test

The next research priority is to validate endpoints against longer-term health outcomes, then test whether candidate longevity products improve those outcomes in humans.

How AgeAmaze helps

Regulatory progress on drugs intended for dogs can be mistaken for evidence about human longevity, so AgeAmaze separates animal evidence from human findings. Its accessible coverage helps skeptical readers interpret biological mechanisms and emerging interventions with context for judging which conclusions are established and which remain tentative.

Read the research

Sources

1. Anti-aging pills and peptides aren’t the legal gray area they seem, but proving they work is harder
2. 21 CFR 101.93 -- Certain types of statements for dietary supplements.